StocksMedium•13 November 2026•
1 min read
Elite Pharmaceuticals Targets NASDAQ Listing by March 2027
Key Facts
1Elite Pharmaceuticals is targeting a move to the NASDAQ exchange by March 2027.
2The company plans to launch a $27 billion anticoagulant drug in 2028.
Elite Pharmaceuticals is targeting a move to the NASDAQ exchange by March 2027. Seeking Alpha reported that the company outlined this transition as part of a strategic roadmap to improve stock liquidity and corporate visibility.
The company also plans to launch an anticoagulant drug in 2028, targeting a market value of $27 billion for the product. These initiatives reflect a focus on advancing a high-value pharmaceutical pipeline while seeking the broader investor reach provided by a major exchange listing.